Philips releases new TissueMark computational pathology software

6 September 2018 (Last Updated September 6th, 2018 12:25)

Health technology major Royal Philips has introduced an updated version of its TissueMark computational pathology solution software at Euskalduna Conference Centre in Bilbao, Spain.

Philips releases new TissueMark computational pathology software
Philips Digital & Computational Pathology. Credit: Koninklijke Philips N.V.

Health technology major Royal Philips has introduced an updated version of its TissueMark computational pathology solution software at Euskalduna Conference Centre in Bilbao, Spain.

The new TissueMark version leverages artificial intelligence (AI) to support region of interest detection for molecular testing as well as assists research labs in enhancing the accuracy of tumour estimation.

It will also offer tumour sufficiency guidance for lung histology, lung cytology, colon and breast tissue samples along with whole slide images (WSI) of adenocarcinoma prostate tissue as well as high-grade serous carcinoma ovarian tissue.

“The new TissueMark version leverages artificial intelligence to support region of interest detection for molecular testing as well as assists research labs in enhancing the accuracy of tumour estimation.”

Philips digital and computational pathology general manager Marlon Thompson said: “Using a microscope for tumour estimation is subjective and leads to high variability amongst pathologists.

“By digitising the tissue slide and analysing the image with robust computational software and intelligent algorithms, we can better support pathologists’ workflows and help labs enhance quality and reliability while reducing costs by limiting the number of molecular tests performed with insufficient tumour content.”

In addition, the company aims to support pathologists’ workflows by digitising the tissue slide and uses computational software and intelligent algorithms to analyse the image.

This will assist labs to improve quality and reliability as well as reduce costs by limiting the number of molecular tests performed with insufficient tumour content.

Earlier this year, the technology company unveiled its AI platform for healthcare.